This finding is supported by IPA prediction (Figure 5); metformin’s predicted inhibition of CXCL-10 could potentially result in reduced vascular damage in T1DM patients would ameliorate CVD risk factor development. The gene discussed is CXCL10; the disease is type 1 diabetes mellitus.